HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alberto-Culver management

This article was originally published in The Rose Sheet

Executive Summary

Firm appoints Ralph J. Nicoletti as senior VP and chief financial officer, announced March 1. The exec previously spent 27 years at Kraft Foods, where he served as VP-corporate audit and, before that, as senior VP-finance for Kraft Foods North America. In addition to personal care products such as Alberto VO5 and St. Ives, Alberto-Culver also markets household products such as Mrs. Dash and Static Guard. Nicoletti's appointment is "an important part of our restructuring as a focused consumer products company," Alberto-Culver President and CEO V. James Marino said. The firm reported financial results for its first quarter of independence in January, after splitting from Sally Beauty in November 2006 (1"The Rose Sheet" Jan. 29, 2007, In Brief)...

You may also be interested in...



Alberto-Culver Q1

Firm reports results of its first quarter (ended Dec. 31) as an independent company Jan. 25, crediting 12.6% increase in sales to $351.1 mil. to strong growth in Nexxus and TRESemme. Gross profit grew 12.3% to $180.9 mil., while earnings were "essentially breakeven" after restructuring costs, firm says. The company increased its ad spend 20.9% to $61 mil. as part of an "ongoing effort to support and further expand our brands," president and CEO V. James Marino said. "This quarter marks a new beginning for Alberto-Culver and its shareholders, and we are focused on our efforts to drive results and create value over the long term," he remarked. Brand announced a "right-sizing" plan in December (1"The Rose Sheet" Dec. 4, 2006, In Brief)...

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014577

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel